A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity

[1]  O. Aslan,et al.  Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. , 2007, American heart journal.

[2]  J. Núñez,et al.  Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. , 2007, International journal of cardiology.

[3]  H. Khalili,et al.  N-acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies , 2006 .

[4]  P. Persson,et al.  Do iodinated contrast media interfere with renal tubular creatinine secretion? , 2006, Radiology.

[5]  J. Vieira,et al.  Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair-a randomized controlled trial. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  F. Veglia,et al.  N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .

[7]  M. Tonelli,et al.  Prophylaxis strategies for contrast-induced nephropathy. , 2006, JAMA.

[8]  M. Hynninen,et al.  N-Acetylcysteine for the Prevention of Kidney Injury in Abdominal Aortic Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial , 2006, Anesthesia and analgesia.

[9]  M. Yamasaki,et al.  [Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  J. Sochman,et al.  Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy. , 2006, Kardiologia polska.

[11]  A. Meining,et al.  Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. , 2006, Radiology.

[12]  S. Puumala,et al.  Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). , 2006, International journal of cardiology.

[13]  Allen J. Taylor,et al.  Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. , 2006, American heart journal.

[14]  C. Sandhu,et al.  The Role of N-Acetylcysteine in the Prevention of Contrast-Induced Nephrotoxicity , 2006, CardioVascular and Interventional Radiology.

[15]  F. McAlister,et al.  Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. , 2006, Archives of internal medicine.

[16]  E. Romagnoli,et al.  Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study , 2006, BMJ : British Medical Journal.

[17]  Omer Toprak.  Letter to the Editor: “Interactions between Serum Creatinine, Volume Status, N-Acetylcysteine, and Contrast-Induced Nephropathy” , 2006, Renal Failure.

[18]  A. Keogh,et al.  Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial. , 2005, Heart, lung & circulation.

[19]  O. Gulel,et al.  Prophylactic Acetylcysteine Usage for Prevention of Contrast Nephropathy after Coronary Angiography , 2005, Journal of cardiovascular pharmacology.

[20]  L. Stitt,et al.  Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial. , 2005, JAMA.

[21]  P. Nery,et al.  N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial , 2005, Heart.

[22]  D. Malenka,et al.  N‐acetylcysteine prophylaxis significantly reduces the risk of radiocontrast‐induced nephropathy: Comprehensive meta‐analysis , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  J. Ix,et al.  N-acetylcysteine for the prevention of contrast-induced nephropathy , 2005, Journal of General Internal Medicine.

[24]  M. Frey,et al.  Effectiveness of acetylcysteine in prevention of contrast nephropathy. , 2005, The Journal of invasive cardiology.

[25]  K. Shojania,et al.  Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. , 2004, The American journal of medicine.

[26]  D. Baker,et al.  Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. , 2004, Journal of vascular surgery.

[27]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[28]  P. McLaughlin,et al.  N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. , 2004, American heart journal.

[29]  A. Levin,et al.  A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. , 2004, American heart journal.

[30]  A. Colombo,et al.  N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity , 2004 .

[31]  D. Feldman,et al.  Lack of efficacy of N-acetylcysteine in attenuating contrast induced nephropathy in patients with severe systolic heart failure , 2004 .

[32]  V. Guru,et al.  The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. , 2004, Clinical nephrology.

[33]  F. Pelliccia,et al.  Comparison of presenting features, diagnostic tools, hospital outcomes, and quality of care indicators in older (>65 years) to younger, men to women, and diabetics to nondiabetics with acute chest pain triaged in the emergency department. , 2004, The American journal of cardiology.

[34]  A. Seguro,et al.  Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  J. Boura,et al.  Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. , 2004, Journal of interventional cardiology.

[36]  R. Bersin,et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. , 2004, JAMA.

[37]  E. Ohman,et al.  Effect of N-Acetylcysteine on Serum Creatinine Concentration in Patients with Chronic Renal Insufficiency Who Are Undergoing Coronary Angiography , 2004, Heart Drug.

[38]  J. Sanderson,et al.  Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  B. Banas,et al.  N-Acetylcysteine in the Prevention of Radiocontrast-Induced Nephropathy: Clinical Trials and End Points , 2004, Kidney and Blood Pressure Research.

[40]  M. Tonelli,et al.  Systematic review of the impact of N-acetylcysteine on contrast nephropathy. , 2004, Kidney international.

[41]  C. Poole,et al.  N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.

[42]  E. Schwammenthal,et al.  Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. , 2004, European heart journal.

[43]  M. Rudnick,et al.  N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. , 2004, Journal of the American Society of Nephrology : JASN.

[44]  B. Krämer,et al.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. , 2004, Journal of the American Society of Nephrology : JASN.

[45]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[46]  P. O'Malley,et al.  Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. , 2003, The American journal of cardiology.

[47]  D. Hilleman,et al.  Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. , 2003, American heart journal.

[48]  J. Morrow,et al.  The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. , 2003, Kidney international.

[49]  G. Helft,et al.  [Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography]. , 2003, Archives des maladies du coeur et des vaisseaux.

[50]  C. Hanet,et al.  Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? , 2003, Acta cardiologica.

[51]  E. Macon,et al.  Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[52]  C. Perlemoine,et al.  Interest of cystatin C in screening diabetic patients for early impairment of renal function. , 2003, Metabolism: clinical and experimental.

[53]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[54]  F. Markowetz,et al.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis , 2003, The Lancet.

[55]  A. Wragg,et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. , 2003, Journal of the American College of Cardiology.

[56]  G. Tadros,et al.  Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. , 2003, The Journal of invasive cardiology.

[57]  D. Denny,et al.  P-597: The effect of acetylcysteine on renal function in elderly high-risk patients exposed to arteriographic contrast dye , 2003 .

[58]  N. Chegini,et al.  Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  Deepak L. Bhatt,et al.  Hydration versus N-acetylcysteine for protection of renal function in patients with renal insufficiency undergoing percutaneous coronary intervention , 2003 .

[60]  D. Vido,et al.  The role of acetylcysteine in preventing contrast-induced nephropathy following cardiac catheterization in patients with acute and chronic renal failure , 2003 .

[61]  G. Stone,et al.  A risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention , 2003 .

[62]  A. Hussain,et al.  Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radio-contrast induced nephropathy , 2003 .

[63]  V. Huckell,et al.  Oral N-acetylcysteine administered immediately prior to routine percutaneous coronary procedures ameliorates contrast-induced nephrotoxicity , 2003 .

[64]  S. Sdringola,et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[65]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[66]  S. Fishbane,et al.  A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. , 2002, Kidney international.

[67]  S. Allaqaband,et al.  Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[68]  Charles Natanson,et al.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. , 2002, American journal of respiratory and critical care medicine.

[69]  K. Shyu,et al.  Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. , 2002, Journal of the American College of Cardiology.

[70]  P. Teirstein,et al.  Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial , 2002, Circulation.

[71]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.

[72]  N. Espinola-Zavaleta,et al.  Comparison of short- and long-term benefits of reperfusion in single-vessel inferior wall acute myocardial infarction with and without right ventricular wall infarction. , 2002, The American journal of cardiology.

[73]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[74]  Adrian E. Raftery,et al.  Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .

[75]  C. Price,et al.  Cystatin C: an improved estimator of glomerular filtration rate? , 2002, Clinical chemistry.

[76]  A. Israni,et al.  Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[77]  S. Marsch,et al.  Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. , 2002, Archives of internal medicine.

[78]  Douglas Losordo,et al.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). , 2002, The American journal of cardiology.

[79]  H. Buhr,et al.  Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block? , 2002, Intensive Care Medicine.

[80]  S G Thompson,et al.  Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. , 2000, Statistics in medicine.

[81]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[82]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[83]  G. Smith,et al.  Meta-analysis: Unresolved issues and future developments , 1998, BMJ.

[84]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[85]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[86]  G. Grégoire,et al.  Discrepancies between meta-analyses and subsequent large randomized, controlled trials. , 1997, The New England journal of medicine.

[87]  C. Viscoli,et al.  The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.

[88]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[89]  C. Tudor-Smith,et al.  Healthy eating in Wales , 1995, BMJ.

[90]  George Davey Smith,et al.  Misleading meta-analysis , 1995, BMJ.

[91]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[92]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[93]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[94]  W. Bank,et al.  Renal failure after major angiography can be avoided with hydration. , 1981, AJR. American journal of roentgenology.

[95]  Rupert G. Miller.  The jackknife-a review , 1974 .

[96]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[97]  W. J. Dixon,et al.  Analysis of Extreme Values , 1950 .

[98]  C. Hennekens,et al.  N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. , 2006, American heart journal.

[99]  J. H. Noble.  Meta-analysis: Methods, strengths, weaknesses, and political uses. , 2006, The Journal of laboratory and clinical medicine.

[100]  P. Cecchini,et al.  Hospital admission of patients referred to the Emergency Department for syncope: a single-hospital prospective study based on the application of the European Society of Cardiology Guidelines on syncope. , 2006, European heart journal.

[101]  Luis S Cremona,et al.  Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography. , 2004, Revista de la Facultad de Ciencias Medicas.

[102]  S. Rezkalla,et al.  Effectiveness of acetylcysteine on preventing renal dysfunction in patients undergoing coronary procedures. , 2004, WMJ : official publication of the State Medical Society of Wisconsin.

[103]  B. Jaber,et al.  Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[104]  S. Bagshaw,et al.  Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis , 2004, BMC medicine.

[105]  D. Baker,et al.  N-Acetylcysteine for the prevention of nephropathy induced by radiographic contrast media in vascular patients undergoing angiography: a randomised, double-blind, controlled trial , 2004 .

[106]  B. Macneill,et al.  Prophylaxis of contrast‐induced nephropathy in patients undergoing coronary angiography , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.